Natural Health Products Relora and Seditol Now Available in Australia through Capitol Ingredients

Share Article

Two widely successful all-natural solutions by Next Pharmaceuticals are now available in Australia: Relora®, which helps alleviate stress, reduce stress-related eating and promote weight loss; and Seditol®, which promotes relaxation and restful sleep

Next Pharmaceuticals products Relora and Seditol are now available in Australia through Capitol Ingredients, a wholly owned Australian company that supplies all-natural, high-quality nutrition, health and personal care ingredients.

Relora is a premier all-natural, anti-stress patented dietary supplement that has been praised and cited in leading publications for helping calm the over-worked and over-stressed. Its unique blend of extracts from the bark of Magnolia officinalis and Phellodendron amurense act to calm the mind and body. Relora has also been shown to help balance cortisol, a stress hormone that can keep the brain in a state of hyperarousal.

Seditol, a patented extract from Magnolia officinalis bark and Ziziphus spinosa seed, is an all-natural sleep product that binds to the receptors in the brain that promote relaxation and sleep. As cited in the highly respected, peer-reviewed Journal of Ethnopharmacoology. Seditol has been scientifically shown to help people fall asleep faster and stay asleep longer with no “hangover,” also reducing the fatigue typically associated with poor sleep.

Relora and Seditol have been widely used in the United States and are now available in Australia through Capitol Ingredients. Capitol’s National Sales Manager Russell Bolden stated, “Capitol Ingredients has a long history of providing high quality, natural healthcare ingredients in Australia and worldwide and we’re pleased to announce our association with Next Pharmaceuticals. Relora and Seditol tick all the right boxes in a tight regulatory environment where the market demands solid, evidence-based products.”

“Relora and Seditol have helped thousands of Americans achieve a better quality of life and cope with chronic health problems related to poor sleep, anxiety and weight management,” said Next Pharmaceuticals CEO, Charles Kosmont. “Both products are widely recommended by physicians and have been consistently recognized in leading U.S. publications, and we look forward to their continued success in Australia.”

Capitol Ingredients is seeking sponsors who are interested in launching Relora and Seditol in the Australia and New Zealand markets. For more information, please contact Julie Brogan at +61 (2) 88144999.

About Next Pharmaceuticals:
Founded in1997, Next Pharmaceuticals (Next) provides patented, science-based natural ingredients for healthy living products in the dietary supplement, food and beverage industries. Next has successfully developed six patented and proprietary plant extracts as well as Chromulin®, a new, safer form of the essential trace mineral chromium. Next products help consumers cope with many of today’s most prevalent and chronic health issues, significantly expanding the choices for self-care products while providing consumer brands with powerful product differentiation. Next proprietary formulations include Relora® for stress, stress-related eating and weight management; Seditol® for improved, more restful sleep; Nexrutine® for inflammation due to over exertion and exercise; Citri-Z® for heart health; Flavoxine® for balanced cholesterol levels; and Citrofen® for joint mobility and comfort. For more information, visit

About Capitol Ingredients:
Founded in 1992, Capitol Ingredients Australia Pty Ltd is a wholly Australian and privately owned company with its head office located in Bella Vista, 35km northwest of Sydney. Capitol Ingredients is the exclusive distributor in Australia and New Zealand for leading manufacturers of high quality and innovative ingredients from around the world. The markets served include the natural health care industry, the home and personal care industry and the food industry.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lora Schwenk Quinn
Next Pharmaceuticals
(678) 778-8968
Email >
Visit website